A Phase 3 interventional study of Saizen® and Placebo and Saizen® in Fibromyalgia, sponsored by Merck KGaA, Darmstadt, Germany. Completed at 1 site in Spain. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-08-02.
Sponsored by Merck KGaA, Darmstadt, Germany · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 151 studies in Fibromyalgia with a site in Spain — 16 open to participants now, 21 under way, none of them phase 3. Fibromyalgia · Spain.
Among the 151 studies in Fibromyalgia with a site in Spain, this one is the 34th largest by enrollment of the 135 interventional ones that give a count, is one of 5 that started in 2007, is one of 14 in phase 3, and was the 15th registered.
1,244 studies on the registry are indexed under Fibromyalgia; 255 are open to participants now.
Browse Fibromyalgia studies →16 of the 151 studies in Fibromyalgia with a site in Spain are open now. Recruiting first, the newest first:
Ionclinics & Deionic SL · Sites in Spain
Ages 18+
European University Miguel de Cervantes · Sites in Spain
Ages 18+ · Women only
University of Valladolid · Sites in Spain
Ages 18+
Cardenal Herrera University · Sites in Spain
Ages 18–80
Parc de Salut Mar · Sites in Spain
Ages 18–70 · Women only
A study can be open while its sites in Spain have not opened yet or have stopped. Only those recruiting at a site in Spain →
Of the 160 Fibromyalgia studies recruiting now, 50 (31%) set no upper age limit and 96 (60%) stop at 75 or younger; 15 take children under 18; 35 take healthy volunteers.
This study: 18 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
151 studies; the count open now beside each. This study's row is marked.
First in 2004; this study’s year is marked. 5 started in 2007.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 113 is above the median of 60 across 938 interventional studies indexed under Fibromyalgia.
Median enrollment 66 across the 135 interventional studies, 90 across the 15 observational. Of the 107 that completed or were terminated, 10 (9%) have results posted.
This tab as a report to print or save as PDF → With an account.
18 of 151 have an industry lead sponsor. The 10 most frequent:
Merck KGaA, Darmstadt, Germany is the lead sponsor of 275 studies on the registry; none are open to participants now.
Merck KGaA, Darmstadt, Germany has 1 study filed under Fibromyalgia — fewer than ten, so there is no comparison to draw.
5 of the studies in Fibromyalgia with a site in Spain that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07424534University of Castilla-La ManchaPredictive Models on Psychosocial Profile, Fatigue and Sleep Quality | 2026-11-30 |
| NCT06948500Cardenal Herrera UniversityEffectiveness of an IVR-based Therapeutic Exercise Program With Altered Visual Feedback in Fibromyalgia Patients | 2026-12-01 |
| NCT07693998University of ValenciaPain Neuroscience Education for Chronic Pain | 2026-12-31 |
| NCT04084795Parc de Salut MarAugmentation of EMDR With tDCS in the Treatment of Fibromyalgia | 2026-12-31 |
| NCT05962437Fundació Sant Joan de DéuSelf-guided Acceptance and Commitment Therapy-based Digital Smartphone Application for Management of Fibromyalgia | 2027-03-31 |
Add all 5 to your calendar (.ics) → With an account.
Among the 151 studies in Fibromyalgia with a site in Spain, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the efficacy of recombinant human growth hormone (r-hGH) treatment in severe fibromyalgia subjects with growth axis dysfunction.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: Saizen®
Drug: Placebo and Saizen®
Saizen® (Somatropin) 0.006 milligram per kilogram (mg/kg) will be administered subcutaneously daily for 12 months. Dose will be titrated (an increase of 0.2 milligram per day) if the increase in insulin-like growth factor 1 (IGF-1) is less than 50 percent of the baseline value. Dose titrations will be made at Month 1, 3, 7 and 9.
Also known as: Somatropin
Placebo matched to Saizen® will be administered for the first 6 months followed by treatment with Saizen® (Somatropin) 0.006 mg/kg subcutaneously daily for next 6 months. Saizen® dose will be titrated (an increase of 0.2 milligram per day) if the increase in insulin-like growth factor 1 (IGF-1) is less than 50 percent of the baseline value. Dose titrations will be made at Month 7 and 9.
Percentage of Participants With Less Than 11 Tender Points at Month 6
The musculoskeletal component in form of pain on palpation in at least 11 of 18 tender point sites is required to fulfill the American College of Rheumatology (ACR) criteria for fibromyalgia syndrome, An important response is considered when the number of tender points falls below 11 since it is the threshold for fibromyalgia diagnosis.
Time frame: Month 6
Percentage of Participants With Less Than 11 Tender Points at Month 12
The musculoskeletal component in form of pain on palpation in at least 11 of 18 tender point sites is required to fulfill the ACR criteria for fibromyalgia syndrome, An important response is considered when the number of tender points falls below 11 since it is the threshold for fibromyalgia diagnosis.
Time frame: Month 12
Fibromyalgia Impact Questionnaire (FIQ) Total Score
Fibromyalgia Impact Questionnaire (FIQ) is a 10-item questionnaire that measures physical impairment, well-being, missed work, pain, fatigue, rest, stiffness, anxiety, and depression. Score ranges from 0 (best result - very well) to 100 (worst result - awful).
Time frame: Baseline, Month 1, 3, 6, 7, 9 and 12
Visual Analog Scale (VAS) Total Score
Visual Analog Scale (VAS) is a 100 millimeter (mm) scale. Intensity of pain range: 0 mm=no pain to 100 mm=worst possible pain.
Time frame: Baseline, Month 1, 3, 6, 7, 9 and 12
EuroQol 5-Dimensions (EQ-5D) Total Score
EuroQol 5-Dimensions (EQ-5D) questionnaire is a measure of health status and quality of life (QoL). The EQ-5D defines health in terms of mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Score range for each item is 0 to 3, with 3 being the most severe. Total score range is 0 to 15. Lower scores represent a better QoL.
Time frame: Baseline, Month 1, 3, 6, 7, 9 and 12
Multidimensional Assessment of Fatigue (MAF) Total Score
Multidimensional Assessment of Fatigue (MAF) consists of 16 questions. The score range for first 14 questions is between 0 and 10 for each question while for the last two questions it is 0 and 4 for each question. Total score range for first 14 questions is 0 to 100 and for last two questions is 0 to 8. Lower scores on the each represent the better participant's condition, whereas, higher scores indicate worsening condition.
Time frame: Baseline, Month 6 and 12
Percentage of Participants With Positive Response on Quality of Life Assessment of Growth Hormone [GH] Deficiency in Adults (QoL AGHDA) Scale
Quality of Life Assessment of GH Deficiency in Adults (QoL AGHDA) questionnaire consists of 25 items that evoke yes or no answers. A score of 1 is given to each item affirmed and these are summed to give the total score. The maximum score is 25, which represents a poor quality of life. The minimum score is 0, which represents a good quality of life. Each question has to be answered with a NO/YES and for each YES, one point is added. The more YES, the higher the score and the worse. Decrease in the positive responses is an index of improvement. So, when the percentage of positive responses on the scale decreases, it is considered a response rate.
Time frame: Baseline, Month 6 and 12
123 subjects were enrolled of whom 113 subjects were randomised and treated.
| Milestone | Saizen® | Placebo + Saizen® |
|---|---|---|
| Started | 55 | 58 |
| Completed | 45 | 47 |
| Not completed | 10 | 11 |
| Withdrew: Protocol violation | 0 | 1 |
| Withdrew: Lost to follow-up | 2 | 2 |
| Withdrew: Withdrawal by subject | 6 | 5 |
| Withdrew: Adverse event | 1 | 1 |
| Withdrew: Physician decision | 1 | 0 |
| Withdrew: Failure to show up at endpoint visits | 0 | 2 |
The musculoskeletal component in form of pain on palpation in at least 11 of 18 tender point sites is required to fulfill the American College of Rheumatology (ACR) criteria for fibromyalgia syndrome, An important response is considered when the number of tender points falls below 11 since it is the threshold for fibromyalgia diagnosis.
| Percentage of participants | Saizen® | Placebo + Saizen® |
|---|---|---|
| Percentage of Participants With Less Than 11 Tender Points at Month 6 | 20 | 22 |
The musculoskeletal component in form of pain on palpation in at least 11 of 18 tender point sites is required to fulfill the ACR criteria for fibromyalgia syndrome, An important response is considered when the number of tender points falls below 11 since it is the threshold for fibromyalgia diagnosis.
| Percentage of participants | Saizen® | Placebo + Saizen® |
|---|---|---|
| Percentage of Participants With Less Than 11 Tender Points at Month 12 | 53 | 34 |
Fibromyalgia Impact Questionnaire (FIQ) is a 10-item questionnaire that measures physical impairment, well-being, missed work, pain, fatigue, rest, stiffness, anxiety, and depression. Score ranges from 0 (best result - very well) to 100 (worst result - awful).
| Units on a scale | Saizen® | Placebo + Saizen® |
|---|---|---|
| Baseline (n=54, 57) | 85.7 ± 2.3 | 86.0 ± 1.8 |
| Month 1 (n=52, 54) | 74.6 ± 3.6 | 73.3 ± 4.7 |
| Month 3 (n=52, 54) | 72.1 ± 4.4 | 66.4 ± 5.1 |
| Month 6 (n=51, 50) | 65.8 ± 4.8 | 68.4 ± 5.3 |
| Month 7 (n=51, 50) | 59.2 ± 5.5 | 65.8 ± 5.7 |
| Month 9 (n=51, 50) | 58.2 ± 6.4 | 65.1 ± 5.7 |
| Month 12 (n=45, 47) | 52.5 ± 6.5 | 64.7 ± 6.5 |
Visual Analog Scale (VAS) is a 100 millimeter (mm) scale. Intensity of pain range: 0 mm=no pain to 100 mm=worst possible pain.
| mm | Saizen® | Placebo + Saizen® |
|---|---|---|
| Baseline (n=54, 57) | 73.3 ± 3.4 | 74.3 ± 3.1 |
| Month 1 (n=52, 54) | 65.1 ± 4.2 | 68.0 ± 5.7 |
| Month 3 (n=52, 54) | 63.7 ± 5.6 | 58.4 ± 5.8 |
| Month 6 (n=51, 50) | 57.6 ± 5.7 | 60.4 ± 6.6 |
| Month 7 (n=51, 50) | 54.6 ± 5.2 | 56.1 ± 6.2 |
| Month 9 (n=51, 50) | 51.2 ± 6.7 | 60.3 ± 6.3 |
| Month 12 (n=45, 47) | 45.0 ± 6.9 | 60.6 ± 6.0 |
EuroQol 5-Dimensions (EQ-5D) questionnaire is a measure of health status and quality of life (QoL). The EQ-5D defines health in terms of mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Score range for each item is 0 to 3, with 3 being the most severe. Total score range is 0 to 15. Lower scores represent a better QoL.
| Units on a scale | Saizen® | Placebo + Saizen® |
|---|---|---|
| Baseline (n=54, 57) | 11.07 ± 0.44 | 11.24 ± 0.42 |
| Month 1 (n=52, 54) | 10.46 ± 0.45 | 10.45 ± 0.42 |
| Month 3 (n=52, 54) | 10.13 ± 0.45 | 10.06 ± 0.55 |
| Month 6 (n=51, 50) | 10.00 ± 0.48 | 10.16 ± 0.56 |
| Month 7 (n=51, 50) | 9.63 ± 0.49 | 9.77 ± 0.54 |
| Month 9 (n=51, 50) | 9.49 ± 0.60 | 9.80 ± 0.50 |
| Month 12 (n=45, 47) | 9.09 ± 0.64 | 9.94 ± 0.56 |
Multidimensional Assessment of Fatigue (MAF) consists of 16 questions. The score range for first 14 questions is between 0 and 10 for each question while for the last two questions it is 0 and 4 for each question. Total score range for first 14 questions is 0 to 100 and for last two questions is 0 to 8. Lower scores on the each represent the better participant's condition, whereas, higher scores indicate worsening condition.
| Units on a scale | Saizen® | Placebo + Saizen® |
|---|---|---|
| 1 to 14 questions: Baseline (n=54, 57) | 90 | 83 |
| 1 to 14 questions: Month 6 (n=51, 50) | 85 | 78 |
| 1 to 14 questions: Month 12 (n=45, 47) | 73 | 78 |
| 15 and 16 question: Baseline (n=54, 57) | 7 | 7 |
| 15 and 16 question: Month 6 (n=51, 50) | 6 | 6 |
| 15 and 16 question: Month 12 (n=45, 47) | 5 | 6 |
Quality of Life Assessment of GH Deficiency in Adults (QoL AGHDA) questionnaire consists of 25 items that evoke yes or no answers. A score of 1 is given to each item affirmed and these are summed to give the total score. The maximum score is 25, which represents a poor quality of life. The minimum score is 0, which represents a good quality of life. Each question has to be answered with a NO/YES and for each YES, one point is added. The more YES, the higher the score and the worse. Decrease in the positive responses is an index of improvement. So, when the percentage of positive responses on the scale decreases, it is considered a response rate.
| Percentage of participants | Saizen® | Placebo + Saizen® |
|---|---|---|
| Baseline (n=54, 57) | 73 | 72 |
| Month 6 (n=51, 50) | 70 | 69 |
| Month 12 (n=45, 47) | 59 | 70 |
Collected over Baseline up to Month 12. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Saizen® | — | 4/55 (7.3%) | 45/55 (81.8%) |
| Placebo + Saizen® | — | 0/58 (0%) | 51/58 (87.9%) |
| Event | Saizen® | Placebo + Saizen® |
|---|---|---|
| Cervix carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/55 | 0/58 |
| Sleep apnoea syndromeNervous system disorders | 1/55 | 0/58 |
| Abdominal pain lowerGastrointestinal disorders | 1/55 | 0/58 |
| Food allergyImmune system disorders | 1/55 | 0/58 |
| Event | Saizen® | Placebo + Saizen® |
|---|---|---|
| HeadacheNervous system disorders | 21/55 | 13/58 |
| OedemaMusculoskeletal and connective tissue disorders | 17/55 | 15/58 |
| FibromyalgiaMusculoskeletal and connective tissue disorders | 1/55 | 16/58 |
| ParaesthesiaNervous system disorders | 13/55 | 6/58 |
| InsomniaNervous system disorders | 9/55 | 2/58 |
| Carpal tunnel syndromeNervous system disorders | 8/55 | 7/58 |
| TachycardiaCardiac disorders | 0/55 | 8/58 |
| HypertriglyceridaemiaMetabolism and nutrition disorders | 0/55 | 8/58 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 4/55 | 8/58 |
| Urinary tract infectionRenal and urinary disorders | 7/55 | 1/58 |
| Age Continuous(years) | Saizen® | Placebo + Saizen® | Total |
|---|---|---|---|
| Mean | 49.9 ± 9.5 | 50.3 ± 9.6 | 50.1 ± 9.5 |
| Sex: Female, Male(Participants) | Saizen® | Placebo + Saizen® | Total |
|---|---|---|---|
| Female | 55 | 58 | 113 |
| Male | 0 | 0 | 0 |
The record gives a start of Dec 2007, a primary completion of Jul 2010 and a completion of Jul 2010. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2013, 3 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2013. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Human Growth Hormone
Merck KGaA, Darmstadt, Germany →